The 2012 AHS/AAN Guidelines for Prevention of Episodic Migraine: A Summary and Comparison With Other Recent Clinical Practice Guidelines

Graham Headache Center and the Department of Neurology, Division of Headache and Pain, Brigham and Women's and Faulkner Hospitals, Boston, MA, USA.
Headache The Journal of Head and Face Pain (Impact Factor: 2.71). 06/2012; 52(6):930-45. DOI: 10.1111/j.1526-4610.2012.02185.x
Source: PubMed


Updated guidelines for the preventive treatment of episodic migraine have been issued by the American Headache Society (AHS) and the American Academy of Neurology (AAN). We summarize key 2012 guideline recommendations and changes from previous guidelines. We review the characteristics, methods, consistency, and quality of the AHS/AAN guidelines in comparison with recently issued guidelines from other specialty societies.
To accomplish this, we reviewed the AHS/AAN guidelines and identified comparable recent guidelines through a systematic MEDLINE search. We extracted key data, and summarized and compared the key recommendations and assessed quality using the Appraisal of Guidelines Research and Evaluation-II (AGREE-II) tool. We identified 2 additional recent guidelines for migraine prevention from the Canadian Headache Society and the European Federation of Neurological Societies. All of the guidelines used structured methods to locate evidence and linked recommendations with assessment of the evidence, but they varied in the methods used to derive recommendations from that evidence.
Overall, the 3 guidelines were consistent in their recommendations of treatments for first-line use. All rated topiramate, divalproex/sodium valproate, propranolol, and metoprolol as having the highest level of evidence. In contrast, recommendations diverged substantially for gabapentin and feverfew. The overall quality of the guidelines ranged from 2 to 6 out of 7 on the AGREE-II tool.
The AHS/AAN and Canadian guidelines are recommended for use on the basis of the AGREE-II quality assessment. Recommendations for the future development of clinical practice guidelines in migraine are provided. In particular, efforts should be made to ensure that guidelines are regularly updated and that guideline developers strive to locate and incorporate unpublished clinical trial evidence.

1 Follower
25 Reads
  • Source
    • "Although the precise mechanism by which neuroleptic drugs alleviate migraine headache pain is unclear, it is likely through dopamine antagonism, as dopamine is thought to play a role in the development of migraine headaches [144]. These data suggest that, following additional study, atypical antipsychotics may be considered for treatment of episodic migraines in patients for whom first-line treatments recommended by the American Headache Society, such as anticonvulsants and beta-blockers, are ineffective, though the impact of side effects must be considered [145]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Undertreatment of pain (oligoanalgesia) in the emergency department is common, and it negatively impacts patient care. Both failure of appropriate pain assessment and the potential for unsafe analgesic use contribute to the problem. As a result, achieving satisfactory analgesia while minimizing side effects remains particularly challenging for emergency physicians, both in the emergency department and after a patient is discharged. Improvements in rapid pain assessment and in evaluation of noncommunicative populations may result in a better estimation of which patients require analgesia and how much pain is present. New formulations of available treatments, such as rapidly absorbed, topical, or intranasal nonsteroidal anti-inflammatory drug formulations or intranasal opioids, may provide effective analgesia with an improved risk-benefit profile. Other pharmacological therapies have been shown to be effective for certain pain modalities, such as the use of antidepressants for musculoskeletal pain, γ-aminobutyric acid agonists for neuropathic and postsurgical pain, antipsychotics for headache, and topical capsaicin for neuropathic pain. Nonpharmacological methods of pain control include the use of electrical stimulation, relaxation therapies, psychosocial/manipulative therapies, and acupuncture. Tailoring of available treatment options to specific pain modalities, as well as improvements in pain assessment, treatment options, and formulations, may improve pain control in the emergency department setting and beyond.
    Hospital practice (1995) 01/2015; 43(1):1-10. DOI:10.1080/21548331.2015.1000794
  • Source
    • "Due to the high prevalence and the substantial clinical and economical burden placed on society, migraine should now be regarded as a public healthcare issue [11] [22]. The current approach for prevention of episodic migraine, as recently endorsed by the American Headache Society (AHS) and the American Academy of Neurology (AAN), is based on administration of topiramate, divalproex/sodium valproate, propranolol, and metoprolol [23]. Among nutritional supplements classified as " probably effective, " only riboflavin (i.e., vitamin B2) is included in the AHS/AAN guidelines. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin D deficiency is associated with a number of human disorders, including cardiovascular disease, cancer, diabetes, frailty, and infections. Since an association between vitamin D and migraine has also been recently speculated, we performed an electronic search on Medline, Scopus, and Web of Science using the keywords "migraine" and "vitamin D," "25OH-D" "cholecalciferol," "ergocalciferol," with no language or date restriction. The electronic search allowed identifying seven studies (3 observational, 2 cross-sectional, and 2 case reports). The two case reports, including four women, showed favourable effects of vitamin D supplementation on migraine severity, but these studies were small and not placebo controlled. As regards the three observational studies, vitamin D deficiency was observed in 13.2 to 14.8% of migraine patients, and these rates do not differ from those reported in the general population (i.e., vitamin D deficiency between 22 and 42%). The results of the two cross-sectional studies are even more controversial, since no association was found between vitamin D status and migraine in both trials. In conclusion, the current evidence suggests that the association between migraine and vitamin D lacks reliable scientific support.
    BioMed Research International 05/2014; 2014:827635. DOI:10.1155/2014/827635 · 3.17 Impact Factor
  • Source
    • "Its high selectivity for the cerebral vasculature, long elimination half life and high persistence of therapeutic action may be useful in preventing menstrual migraine, but also for treating acute attacks, as shown by several randomized trials [4–7]. Although frovatriptan is currently among the triptans recommended for prevention of menstrual migraine [8–10], its efficacy in OCMM has had limited investigation [11]. In the present retrospective analysis, we report on a pooled individual data analysis of three randomized double-blind studies [12–14] performed to verify whether frovatriptan may be effective in the acute management of an OCMM attack and whether its efficacy may differ from that of other triptans. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Oral contraceptive-induced menstrual migraine (OCMM) is a particularly severe form of migraine triggered by the cyclic hormone withdrawal. To review the efficacy of frovatriptan vs. other triptans, in the acute treatment of OCMM through a pooled analysis of three individual randomized Italian studies. With or without aura migraineurs were randomized to frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). All studies had a multicenter, randomized, double-blind, crossover design. After treating 1-3 episodes of migraine in 3 months with the first treatment, patients switched to the other treatment for the next 3 months. In this analysis, the subset of 35 of the 280 women of the intention-to-treat population taking combined oral contraceptives and experiencing a migraine attack during the withdrawal phase, were analyzed. The proportion of pain free and pain relief at 2 h were 25 and 51 % with frovatriptan and 28 and 48 % with comparators (p = NS). At 24 h, 71 and 83 % of frovatriptan-treated patients and 60 and 76 % of comparator-treated patients were pain free (p < 0.05 between treatments) and had pain relief (p = NS), respectively. Relapse at 24 and 48 h was significantly (p < 0.05) lower with frovatriptan (17 and 21 %) than with the comparators (27 and 31 %). Our results suggest that, due to its sustained antimigraine effect, frovatriptan may be particularly suitable for the management of OCMM than other triptans.
    Neurological Sciences 05/2013; 34 Suppl 1(S1):83-6. DOI:10.1007/s10072-013-1393-x · 1.45 Impact Factor
Show more


25 Reads
Available from